Correlation between the International Neuroblastoma Pathology Classification and genomic signature in neuroblastoma

Atsuko Nakazawa, Chizuko Haga, Miki Ohira, Hajime Okita, Takehiko Kamijo, Akira Nakagawara

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The International Neuroblastoma Pathology Classification (INPC) has a prognostic impact that distinguishes two categories of neuroblastoma: favorable histology (FH) and unfavorable histology (UH). We analyzed 92 cases of neuroblastoma with the INPC evaluation and genomic grouping to investigate the correlation between the INPC and genomic signature, together with their prognostic significance. The correlation of UH tumor and partial gains and/or losses (GGP), as well as the correlation of FH tumor and whole gains and/or losses (GGW), was statistically significant. Both UH and GGP were late-onset (median age at diagnosis was 36 and 48 months, respectively) and had poor prognosis (overall survival rate [OS], 43.1% and 42.4%, respectively). In contrast, both FH and GGW were early-onset (median age at diagnosis, 4 and 9.5 months, respectively) and had favorable prognosis (OS, 88.6% and 87.1%, respectively). Unfavorable histology and GGP had significantly inferior OS compared to FH and GGW. Overall survival was not significantly different among the genomic groups in FH; however, it was inferior in UH with GGP. In UH with a single copy MYCN, genomic subgroups GGP2s (both 1p and 11q losses) and GGP3s (partial 11q loss but not 1p loss) indicated significantly poor prognosis compared to GGP4s (no partial 1p and 11q loss). As INPC and MYCN amplification were found to be the most powerful prognostic biological factors, they should be included with genomic grouping as treatment stratification for patients with UH and single copy of MYCN.

Original languageEnglish
Pages (from-to)766-771
Number of pages6
JournalCancer Science
Volume106
Issue number6
DOIs
Publication statusPublished - 2015 Jun 1
Externally publishedYes

Fingerprint

Neuroblastoma
Histology
Pathology
Survival Rate
Age of Onset
Biological Factors
Neoplasms

Keywords

  • Array comparative genomic hybridization
  • Neuroblastoma
  • Pathology
  • Risk assessment
  • Risk factors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Correlation between the International Neuroblastoma Pathology Classification and genomic signature in neuroblastoma. / Nakazawa, Atsuko; Haga, Chizuko; Ohira, Miki; Okita, Hajime; Kamijo, Takehiko; Nakagawara, Akira.

In: Cancer Science, Vol. 106, No. 6, 01.06.2015, p. 766-771.

Research output: Contribution to journalArticle

Nakazawa, Atsuko ; Haga, Chizuko ; Ohira, Miki ; Okita, Hajime ; Kamijo, Takehiko ; Nakagawara, Akira. / Correlation between the International Neuroblastoma Pathology Classification and genomic signature in neuroblastoma. In: Cancer Science. 2015 ; Vol. 106, No. 6. pp. 766-771.
@article{b9c251252a2342ab88be916ee246b6f5,
title = "Correlation between the International Neuroblastoma Pathology Classification and genomic signature in neuroblastoma",
abstract = "The International Neuroblastoma Pathology Classification (INPC) has a prognostic impact that distinguishes two categories of neuroblastoma: favorable histology (FH) and unfavorable histology (UH). We analyzed 92 cases of neuroblastoma with the INPC evaluation and genomic grouping to investigate the correlation between the INPC and genomic signature, together with their prognostic significance. The correlation of UH tumor and partial gains and/or losses (GGP), as well as the correlation of FH tumor and whole gains and/or losses (GGW), was statistically significant. Both UH and GGP were late-onset (median age at diagnosis was 36 and 48 months, respectively) and had poor prognosis (overall survival rate [OS], 43.1{\%} and 42.4{\%}, respectively). In contrast, both FH and GGW were early-onset (median age at diagnosis, 4 and 9.5 months, respectively) and had favorable prognosis (OS, 88.6{\%} and 87.1{\%}, respectively). Unfavorable histology and GGP had significantly inferior OS compared to FH and GGW. Overall survival was not significantly different among the genomic groups in FH; however, it was inferior in UH with GGP. In UH with a single copy MYCN, genomic subgroups GGP2s (both 1p and 11q losses) and GGP3s (partial 11q loss but not 1p loss) indicated significantly poor prognosis compared to GGP4s (no partial 1p and 11q loss). As INPC and MYCN amplification were found to be the most powerful prognostic biological factors, they should be included with genomic grouping as treatment stratification for patients with UH and single copy of MYCN.",
keywords = "Array comparative genomic hybridization, Neuroblastoma, Pathology, Risk assessment, Risk factors",
author = "Atsuko Nakazawa and Chizuko Haga and Miki Ohira and Hajime Okita and Takehiko Kamijo and Akira Nakagawara",
year = "2015",
month = "6",
day = "1",
doi = "10.1111/cas.12665",
language = "English",
volume = "106",
pages = "766--771",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Correlation between the International Neuroblastoma Pathology Classification and genomic signature in neuroblastoma

AU - Nakazawa, Atsuko

AU - Haga, Chizuko

AU - Ohira, Miki

AU - Okita, Hajime

AU - Kamijo, Takehiko

AU - Nakagawara, Akira

PY - 2015/6/1

Y1 - 2015/6/1

N2 - The International Neuroblastoma Pathology Classification (INPC) has a prognostic impact that distinguishes two categories of neuroblastoma: favorable histology (FH) and unfavorable histology (UH). We analyzed 92 cases of neuroblastoma with the INPC evaluation and genomic grouping to investigate the correlation between the INPC and genomic signature, together with their prognostic significance. The correlation of UH tumor and partial gains and/or losses (GGP), as well as the correlation of FH tumor and whole gains and/or losses (GGW), was statistically significant. Both UH and GGP were late-onset (median age at diagnosis was 36 and 48 months, respectively) and had poor prognosis (overall survival rate [OS], 43.1% and 42.4%, respectively). In contrast, both FH and GGW were early-onset (median age at diagnosis, 4 and 9.5 months, respectively) and had favorable prognosis (OS, 88.6% and 87.1%, respectively). Unfavorable histology and GGP had significantly inferior OS compared to FH and GGW. Overall survival was not significantly different among the genomic groups in FH; however, it was inferior in UH with GGP. In UH with a single copy MYCN, genomic subgroups GGP2s (both 1p and 11q losses) and GGP3s (partial 11q loss but not 1p loss) indicated significantly poor prognosis compared to GGP4s (no partial 1p and 11q loss). As INPC and MYCN amplification were found to be the most powerful prognostic biological factors, they should be included with genomic grouping as treatment stratification for patients with UH and single copy of MYCN.

AB - The International Neuroblastoma Pathology Classification (INPC) has a prognostic impact that distinguishes two categories of neuroblastoma: favorable histology (FH) and unfavorable histology (UH). We analyzed 92 cases of neuroblastoma with the INPC evaluation and genomic grouping to investigate the correlation between the INPC and genomic signature, together with their prognostic significance. The correlation of UH tumor and partial gains and/or losses (GGP), as well as the correlation of FH tumor and whole gains and/or losses (GGW), was statistically significant. Both UH and GGP were late-onset (median age at diagnosis was 36 and 48 months, respectively) and had poor prognosis (overall survival rate [OS], 43.1% and 42.4%, respectively). In contrast, both FH and GGW were early-onset (median age at diagnosis, 4 and 9.5 months, respectively) and had favorable prognosis (OS, 88.6% and 87.1%, respectively). Unfavorable histology and GGP had significantly inferior OS compared to FH and GGW. Overall survival was not significantly different among the genomic groups in FH; however, it was inferior in UH with GGP. In UH with a single copy MYCN, genomic subgroups GGP2s (both 1p and 11q losses) and GGP3s (partial 11q loss but not 1p loss) indicated significantly poor prognosis compared to GGP4s (no partial 1p and 11q loss). As INPC and MYCN amplification were found to be the most powerful prognostic biological factors, they should be included with genomic grouping as treatment stratification for patients with UH and single copy of MYCN.

KW - Array comparative genomic hybridization

KW - Neuroblastoma

KW - Pathology

KW - Risk assessment

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=84930413485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930413485&partnerID=8YFLogxK

U2 - 10.1111/cas.12665

DO - 10.1111/cas.12665

M3 - Article

VL - 106

SP - 766

EP - 771

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 6

ER -